The Zenflow Spring System Safety and Performance Study (ZEST CAN)

Benign Prostatic Hyperplasia Clinical Trial

Official title:

The Zenflow Spring System Safety and Performance Study (ZEST CAN)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04309695
• Other study ID #: CLIN-0111
• Status: Recruiting
• Phase: N/A
• Start date: February 9, 2021
• Est. completion date: January 1, 2026

Study information

• Verified date: August 2020
• Source: Zenflow, Inc.
• Contact: Emily Hu
• Phone: 5109098237
• Email: emily[@]zenflow.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The objectives of the trial are to demonstrate the safety and performance of the Zenflow Spring System in relieving the symptoms of obstructive Benign Prostatic Hyperplasia (BPH).

Description:

The purpose of the Zenflow Study (ZEST CAN) is to evaluate the safety, performance and effectiveness of the Zenflow Spring System for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hyperplasia (BPH). It is intended that the features of the Zenflow Spring will provide an effective office-based treatment and management therapy for BPH with little or no side effects.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 40
• Est. completion date: January 1, 2026
• Est. primary completion date: December 1, 2025
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 45 Years and older

Eligibility

Inclusion Criteria:

1. Patient is able and willing to comply with all the assessments of the study

2. Patient or patient's legal representative has been informed of the nature of the study, agrees to participate and has signed the informed consent form

3. = 45 years of age

4. Baseline IPSS score > 13

5. Prostate volume 25 - 80 cc and prostatic urethral length between 2.5-4.5 cm measured within the past 90 days

6. Failed, intolerant, or patient choice to not take a medication regimen for the treatment of LUTS

Exclusion Criteria:

1. Obstructive intravesical median prostatic lobe which in the opinion of the operator would not benefit from treatment

2. Urethral stricture, meatal stenosis, or bladder neck obstruction - either current, or recurrent requiring 2 or more dilations as reported in the patient's history

3. Requiring self-catheterization to void.

4. Baseline PSA > 10 ng/mL or confirmed or suspected prostate cancer

5. Any of the following, taken from a single uroflowmetry reading:

1. Post-void residual volume (PVR) > 250 ml

2. Peak urinary flow rate of > 15 ml/second

3. < 125 ml urinary volume voided at baseline (pre-bladder urinary volume of =150 ml required)

6. Other condition or disease that might cause urinary retention

7. History of other diseases causing voiding dysfunction

8. Concomitant Urinary Tract Infection (UTI) (subject can be enrolled following successful treatment of UTI and a clean urine test), or subjects who have a history of recurrent or chronic UTIs (defined as 2 or more UTIs in the past 12 months)

9. Concomitant bladder stones

10. Previous pelvic irradiation or radical pelvic surgery

11. Previous prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate

12. Chronic prostatitis, or recurring prostatitis within the past 12 months

13. Known allergy to nickel

14. Life expectancy less than 24 months

15. Use of concomitant medications (e.g., anticholinergics, antispasmodics or tricyclic antidepressants) affecting bladder function

16. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure (low dose aspirin therapy not prohibited).

17. Taking 5-alpha-reductase inhibitors within 3 months of pre-treatment (baseline) evaluation

18. Taking one of the following within 2 weeks of pre-treatment (baseline) evaluation:

1. alpha-blockers,

2. imipramine,

3. anticholinergics, or

4. cholinergic medication gonadotropin releasing hormonal analogs

19. Taking androgens, unless evidence of eugonadal state for at least 6 months.

20. Taking one of the following within 24 hours of pre-treatment (baseline) evaluation:

1. phenylephrine, or

2. pseudoephedrine

21. Future fertility concerns

22. Any concurrent medical condition or illness that might prevent study completion or would confound study results

Related Conditions & MeSH terms

• Benign Prostatic Hyperplasia
• Hyperplasia
• Prostatic Hyperplasia

Intervention

Device:
• Zenflow Spring System
The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.

Locations

Country	Name	City	State
Canada	Groupe Sante Brunswick	Pointe-Claire	Quebec
Canada	Toronto Western Hospital	Toronto	ONT

Sponsors (1)

Lead Sponsor	Collaborator
Zenflow, Inc.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Successful placement of the Zenflow Spring Implant	Number of successful deployments and procedural successes for the Zenflow System to implant the Spring device in the OR, or in an out-patient clinical setting as compared to total treatment attempts.	Day of discharge up to 7 days following device placement
Primary	Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH) using the International Prostate Symptom Score	At 3 months, achieve at least 30% mean improvement in International Prostate Symptom Score (IPSS) compared to baseline. The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible. The responses to the 7 questions are tallied for a total IPSS score.	3 month
Primary	Need for urinary catheterization	Achieve < 12% rate of extended post-operative urinary catheterization, defined as an occurrence of a subject requiring catheterization within the first 3 days as part of a postoperative management for inability to void, for greater than 7 days.	7 days after the procedure
Primary	Incidence of procedure or device related serious adverse events	Achieve < 12% rate of device or procedure related SAEs through discharge and 30 days follow up.	30 days after the procedure
Secondary	Assessment of Sexual Health Assessment: Change in sexual health measured by change in the Sexual Health Inventory for Men (SHIM) questionnaire score	The patient selects the most appropriate response to 5 questions about his sexual health. Each response has an assigned value between 1 and 5. The numeric values are tallied for a total score.	Baseline, 3, 6, 12, 24, 36, 48, & 60 months
Secondary	Assessment of Pain, evaluated using a Visual Analog Score (VAS) of 1 to 10	Patient describes pain on a Visual Analog Scale (VAS). The scale is a line labeled 1 at the far left indicating minimal pain and 10 on the right, which is maximum pain.	Baseline, interoperative (if conscious sedation used), immediately post-treatment, 2 weeks, 1 and 3 months
Secondary	Assessment of Adverse Events	Rate of adverse events related to the procedure or device.	Up to 5 years
Secondary	Assessment of Clavien-Dindo events	Proportion of subjects with procedure or device related adverse events classified as Clavien-Dindo Grade 3 or higher or any event resulting in persistent disability evidenced through 3 months post treatment.	Up to 5 years
Secondary	Assessment of PSA	Change in PSA from baseline through 12, 24, 36, 48, & 60 months post treatment.	Up to 5 years
Secondary	Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)	The patient is asked to respond to 7 questions related to his urinary health using a rating scale of 0 to 5 where zero is excellent and 5 is the worst possible. The responses to the 7 questions are tallied for a total score	Baseline, 2 weeks, 1, 6, 12, 24, 36, 48, & 60 months
Secondary	Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)	Improvement in flow of urine as measured by uroflowmetry machine.	Baseline, 2 weeks, 1, 3, 6, 12, 24, 36, 48, & 60 months
Secondary	Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)	Incidence of increase in dosage or initiation of new medication to treat symptoms of BPH.	Up to 5 years
Secondary	Effectiveness of the Spring Implant in reducing symptoms of Benign Prostatic Hyperplasia (BPH)	Incidence of repeat treatment.	24 to 60 months